Novavax brings in Tesaro’s Covino as it readies to market two vaccines; plus moves at Werewolf, Editas, Magenta, Pharming, Marinus and more
Novavax Inc. (NASDAQ:NVAX) hired Gregory Covino as EVP and CFO as the company prepares to commercialize COVID-19 vaccine candidate NVXCoV2373 and flu vaccine NanoFlu. Covino succeeds EVP John Trizzino, who will become chief commercial officer while continuing to serve as CBO. Covino was group CFO of the Tesaro oncology division of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), where he also served as SVP and chief accounting officer. Novavax also promoted CMO Filip Dubovsky to EVP and Biegie Lee to SVP and chief information officer.
Immunomodulatory therapy company Werewolf Therapeutics, which debuted last year, appointed Randi Isaacs as CMO. Isaacs was executive director and clinical site head of translational clinical oncology at the Novartis Institutes for BioMedical Research (NIBR)...